Valeant: Up 6.8%, But Still Not a Buy?
November 08, 2017 at 15:02 PM EST
Shares of Valeant Pharmaceutical International (VRX) continued to climb today on the heels of yesterday’s estimate-beating earnings report. The shares spiked more than 6.8% today to just under $15 a share. Is all this the excitement warranted? Deutsche Bank analyst Gregg Gilbert concedes that Valeant is making “more progress” in rebuilding itself and regaining investors’ confidence […]